Literature DB >> 28270486

Polypoidal choroidal vasculopathy: a common type of neovascular age-related macular degeneration in Caucasians.

Sohraab Yadav1, David G Parry1, Nick A V Beare1, Ian A Pearce1.   

Abstract

AIMS: To describe the prevalence of polypoidal choroidal vasculopathy (PCV) in a Caucasian population with neovascular age-related macular degeneration (NAMD).
METHODS: All patients referred to a city AMD service over a 2-year period underwent imaging including Indocyanine Green Angiography at baseline. A panel of experts confirmed the patients with NAMD and diagnosed the lesion type including PCV. The proportion of Caucasian patients with PCV was identified. Two authors independently reviewed clinical imaging and recorded data of patients with PCV on lesion characteristics. Further information including treatments received and visual acuity at different time points was analysed.
RESULTS: A total of 492 patients were diagnosed with NAMD during the 2-year study period. Of these patients, 204 had occult lesions (41.5%). PCV was identified in 45 patients (22.1% of occult NAMD and 9.1% of all NAMD). 23 patients received anti-vascular endothelial growth factor (VEGF) monotherapy, 8 received verteporfin photodynamic therapy (PDT) monotherapy and the remaining 14 patients were managed with combined PDT and anti-VEGF treatment.
CONCLUSIONS: The prevalence of PCV in Caucasians is higher than previously reported. Indocyanine Green Angiography should be a standard investigation for all new patients with NAMD, particularly those with occult NAMD, to avoid missing this important subset. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Diagnostic tests/Investigation; Epidemiology; Macula; Neovascularisation; Treatment Lasers

Mesh:

Substances:

Year:  2017        PMID: 28270486     DOI: 10.1136/bjophthalmol-2016-310074

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  16 in total

Review 1.  Idiopathic polypoidal choroidal vasculopathy: a review of literature with clinical update on current management practices.

Authors:  Yamini Sahu; Niharika Chaudhary; Mukesh Joshi; Aastha Gandhi
Journal:  Int Ophthalmol       Date:  2020-10-20       Impact factor: 2.031

2.  [Increasing lipid exudation and vascular alterations associated with a choroidal nevus].

Authors:  P Lauermann; N Feltgen; M Khattab; M Storch; H Hoerauf
Journal:  Ophthalmologe       Date:  2018-12       Impact factor: 1.059

3.  Age-related differences in the prevalence of subtypes of Neovascular age-related macular degeneration in the first diagnosed eye.

Authors:  Jae Hui Kim; Young Suk Chang; Jong Woo Kim; Chul Gu Kim; Dong Won Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-01-07       Impact factor: 3.117

4.  Comparison of 3-year outcomes of photodynamic therapy combined with intravitreal ranibizumab or aflibercept for polypoidal choroidal vasculopathy in a European cohort.

Authors:  Siyin Liu; Ramandeep Chhabra
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-06-09       Impact factor: 3.535

5.  Clinical outcomes in Caucasian patients with polypoidal choroidal vasculopathy.

Authors:  Eleftherios I Agorogiannis; Ian A Pearce; Sohraab Yadav; David G Parry; Nicholas A V Beare
Journal:  Eye (Lond)       Date:  2018-07-12       Impact factor: 3.775

Review 6.  The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration.

Authors:  Kelvin Yi Chong Teo; Mark Gillies; Samantha Fraser-Bell
Journal:  Int J Mol Sci       Date:  2018-09-03       Impact factor: 5.923

7.  Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study.

Authors:  Kanji Takahashi; Masahito Ohji; Hiroko Terasaki; Shigeru Honda; Philippe Margaron; Tadhg Guerin; Mitsuko Yuzawa
Journal:  Clin Ophthalmol       Date:  2018-09-13

8.  REAL-WORLD EFFECTIVENESS AND SAFETY OF RANIBIZUMAB TREATMENT IN PATIENTS WITH AND WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY: Twelve-Month Results From the LUMINOUS Study.

Authors:  Adrian Koh; Timothy Y Y Lai; Wen Bin Wei; Ryusaburo Mori; Harumi Wakiyama; Kyu Hyung Park; Fariza Ngah; Wayne Macfadden; Cornelia Dunger-Baldauf; Soumil Parikh
Journal:  Retina       Date:  2020-08       Impact factor: 3.975

9.  Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial.

Authors:  Tock H Lim; Timothy Y Y Lai; Kanji Takahashi; Tien Y Wong; Lee-Jen Chen; Paisan Ruamviboonsuk; Colin S Tan; Won Ki Lee; Chui Ming Gemmy Cheung; Nor Fariza Ngah; Ramune Patalauskaite; Philippe Margaron; Adrian Koh
Journal:  JAMA Ophthalmol       Date:  2020-09-01       Impact factor: 7.389

10.  Pharmacogenomic study on anti-VEGF medicine in treatment of macular Neovascular diseases: a study protocol for a prospective observational study.

Authors:  Jin Jing; Shen Yinchen; Chen Xia; Wang Jing; Chen Chong; Xu Xun; Huang Hengye; Liu Kun
Journal:  BMC Ophthalmol       Date:  2018-07-24       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.